Medtronic Says Study Results Show High Survival Rate for CoreValve

Medtronic, Inc.

today announced new findings from the Medtronic CoreValve ADVANCE Study for 1-year survival and health-related quality of life (HRQoL). The findings were presented this week at Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2012 in Miami. Initial 1-year results of the ADVANCE Study revealed that patients experienced high survival rates, with 1-year survival at 82.1 percent and 1-year cardiovascular survival at 88.2 percent.